The effect of selective serotonin reuptake inhibitors (SSRIs) on the pharmacokinetics and metabolism of perazine in the rat

Journal of Pharmacy and Pharmacology

Volumn 53, Issue 4, 2001, Pages 449-461

  Daniel, W A ^a   Syrek, M ^a   Haduch, A ^a   Wojcikowski J ^a  

^a INSTITUTE OF PHARMACOLOGY   (Poland)

Author keywords

[No Author keywords available]

Indexed keywords

5 SULFOXIDE; CYTOCHROME P450; DRUG METABOLITE; FLUOXETINE; FLUVOXAMINE; NORPERAZINE; PERAZINE; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DEMETHYLATION; DRUG BLOOD LEVEL; DRUG BRAIN LEVEL; DRUG EFFECT; DRUG METABOLISM; ENZYME ACTIVE SITE; IN VITRO STUDY; IN VIVO STUDY; LIVER MICROSOME; MALE; NONHUMAN; RAT STRAIN;

ANIMALS; BRAIN; DOPAMINE ANTAGONISTS; DRUG INTERACTIONS; FLUOXETINE; FLUVOXAMINE; INFUSIONS, PARENTERAL; MALE; PERAZINE; RATS; RATS, WISTAR; SEROTONIN UPTAKE INHIBITORS; SERTRALINE;

EID: 0035038787     PISSN: 00223573     EISSN: None     Source Type: Journal    
DOI: 10.1211/0022357011775749     Document Type: Article

References (47)

1. Interaction between fluoxetine and haloperidol: Pharmacokinetic and clinical implications
2. Significance of neuroleptic dose and plasma level in the pharmacological treatment of psychoses
3. Quantification and mechanism of the fluoxetine and tricyclic antidepressant interaction
4. Urinary metabolites of 10-[3′-(4″-methylpiperazinyl)-prophyl]-phenothiazine (Perazine) in psychiatric patients - I. Isolation, identification and determination of metabolites
5. Accumulation and elimination of a novel metabolite during chronic administration of the phenothiazine drug perazine to rats
6. Prediction and evaluation criteria in perazine therapy of acute schizophrenics. Pharmacokinetic data
7. Role of P4502D6, the target of the sparteine-debrisoquine oxidation polymorphism, in the metabolism of imipramine
8. Fluvoxamine is a potent inhibitor of cytochrome P4501A2
9. Influence of dose and route of administration on the kinetics of fluoxetine and its metabolite norfluoxetine in the rat
10. The effect of selective re-uptake inhibitors on cytochrome P4502D6 (CYP2D6) activity in human liver microsomes
11. Disposition of perphenazine is related to the polymorphic hydroxylation in human beings
12. Lysosomal trapping as an important mechanism involved in the cellular distribution of perazine and in pharmacokinetic interaction with antidepressants
13. Pharmacokinetics of phenothiazine neuroleptics after chronic coadministration of carbamazepine
14. The influence of selective serotonin reuptake inhibitors (SSRIs) on the pharmacokinetics of thioridazine and its metabolites: In vivo and in vitro studies
15. The influence of selective serotonin reuptake inhibitors on the plasma and brain pharmacokinetics of the simplest phenothiazine neuroleptic promazine in the rat
16. Comparison of desmethylsertraline with sertaline as a monoamine uptake inhibitor in vivo
17. A placebo-controlled trial of fluoxetine added to neuroleptic in patients with schizophrenia
18. Molecular genetics of the P-450 Superfamily
19. Pharmacokinetic optimisation of therapy with newer antidepressants
20. Dose-dependent inhibition of CYP1A2, CYP2C19 and CYP2D6 by citalopram, fluetone, fluvoxamine and paroxetine
21. Urinary metabolites of 10-[3′-(4″-methylpiperazinyl)-propyl]-phenothiazine (Perazine) in psychiatric patients - II. Individual metabolite patterns and their changes in the course of treatment
22. Pharmacologic treatment of schizoaffective disorder
23. The effect of selective serotonin reuptake inhibitors and their metabolites on S-mephenytoin 4′-hydroxylase activity in human liver microsomes
24. Sertraline N-demethylation is catalyzed by multiple isoforms of human cytochrome P-450 in vitro
25. The SSRIs: Advantages, disadvantages and differences
26. Antipeptide antibodies targeted against specific regions of rat CYP2D1 and human 2D6
27. Protein measurement with the Folin phenol reagent
28. Effects of sertraline and citalopram given repeatedly on the responsiveness of 5-HT receptor subpopulations
29. Effects of fluoxetine given chronically on the responsiveness of 5-HT receptor subpopulations to their agonists
30. The influence of neuroleptics on the behavioural effect of 5-hydroxytryptophan
31. Some central effects of repeated treatment with fluvoxamine
32. Impact of clinical pharmacokinetics on neuroleptic therapy in patients with schizophrenia
33. Reversal of stress-induced anhedonia by the atypical antidepressants, fluoxetine and maprotyline
34. Combined treatment strategies in psychiatry
35. The carbon monoxide-binding pigment of liver microsomes. I. Evidence for its hemoprotein nature
36. A new method for simultaneous purification of cytochrome b and NADPH-cytochrome reductase from at liver microsomes
37. Paroxetine potentiates the central nervous system side effects of perphenazine: Contribution of cytochrome P4502D6 inhibition in vivo
38. Clinically relevant pharmacology of selective serotonin reuptake inhibitors
39. Monitoring of serum bioactivity levels of perazine and its metabolites by radioreceptor assay
40. Fluvoxamine improves negative symptoms in treated chronic schizophrenia: An add on double blind, placebo-controlled study
41. Hydroxylation of desmethylimipramine: Dependence on debrisoquin hydroxylation phenotype
42. Selective serotonin reuptake inhibitors and CNS drug interactions. A critical review of the evidence
43. Inhibition of desipramine 2-hydroxylation by quinidine and quinine
44. Metabolism and disposition of the 5-hydroxytryptamine uptake blocker sertraline in the rat and dog
45. Pharmacokinetics of neuroleptics
46. Inhibition of alprazolam and desipramine hydroxylation in vitro by paroxetine and fluvoxamine: Comparison with other selective serotonin reuptake inhibitor anti-depressants
47. Validity, reliability and utility of the chronic mild stress model of depression: A 10-year review and evaluation